Vivesto Ab · OMXSTO:VIVE
Vivesto Ab — Oasmia Pharmaceutical — BioEurope 2020
16 slides from Vivesto Ab's conference presentation, Oct 26, 2020
Slide 1: BioEurope Presentation – Seeking Opportunities in Oncology
BIOEUROPE PRESENTATION – SEEKING OPPORTUNITIES IN ONCOLOGY F. R. Martelet, M.D., CEO 26 – 29 October 2020 1
Slide 2: Forward-looking statement
Forward-looking statement IMPORTANT NOTICE The information in this presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require p
Slide 3: Oasmia – an innovation-focused specialty pharmaceutical company
Oasmia – an innovation-focused specialty pharmaceutical company NASDAQ Stockholm 2010 Founded in 1999 Market Cap approx. SEK 2.0 B Based in Uppsala, Sweden XR-17™ technology platform Enhances the intravenous delivery of R&D-focused Production established and novel drugs in Facility in Uppsala, Swede
Slide 4: The new team leading Oasmia's transformation
The new team leading Oasmia’s transformation FRANCOIS MARTELET, M.D., Master’s Degree Business FREDRIK JÄRRSTEN* ELIN TRAMPE, Chief Executive Officer Chief Finance Officer Chief Technical Previous experience: Officer CEO in Biotechnology/ BioPharma in UK, Denmark, US and senior executive global REIN
Slide 5: Meeting the challenges of poor drug solubility
Meeting the challenges of poor drug solubility POOR API1 c.40% OF APPROVED A FACTOR IN SERIOUS $180 bn SOLUBILITY DRUGS AFFECTED2 ADVERSE EVENTS (SAEs) SPENT ON PHARMA R&D EVERY YEAR 3 Solubility enhancers Major challenge in 70-90% of pipeline can cause SAEs and/ drug development drugs classed as or
Slide 6: XR-17 powerful platform that can increase solubility of insoluble compounds
XR-17™ powerful platform that can increase solubility of insoluble compounds Active Pharmaceutical Ingredient XR-17™ XR-17™ + API (API) Hydrophilic head WATER INSOLUBLE Hydrophobic chain WATER SOLUBLE XR-17™ increases small molecule solubility and potentially improves safety and efficacy of new form
Slide 7: XR-17 – the solution to your water solubility issues
XR-17TM – the solution to your water solubility issues XR-17™ ANIMAL OTHER ONCOLOGY HEALTH THERAPEUTIC AREAS Lung Cervical cancer cancer Lymph- Masto- Prostate Breast Ovarian Bladder oma cytoma cancer cancer cancer cancer Paccal Vet Doxophos Vet Docetaxel Micellar 7
Slide 8: XR-17 – platform validated by success of Apealea in oncology
XR-17™ – platform validated by success of Apealea® in oncology Drug load capacity, enabling Strong, validated safety in cancer high drug delivery capability indication1 No mandatory or limited need for Shorter infusion time1,2 steroid pre-medication1 Superior solubility compared with Free from alcoh
Slide 9: Building a diverse portfolio based on XR-17 platform technology
Building a diverse portfolio based on XR-17™ platform technology Registration / Product Indication Pre-clinical Phase I Phase II Phase III approval Geography Human Health Portfolio Apealea® / Ovarian cancer Pre-NDA meeting USA Paclical® (paclitaxel) Ovarian cancer EU / EEA Docetaxel Prostate cancer
Slide 10: Apealea – offering an improved treatment option
Apealea® – offering an improved treatment option Current standard of care in Ovarian cancer is carboplatin + paclitaxel Approved in EU/EEA for A subset of patients cannot tolerate solvent-based paclitaxel treatment of first relapse ovarian cancer1 and in Apealea® is a solvent-free IV formulation of
Slide 11: Apealea – global partnership worth up to $698m + royalties
Apealea® – global partnership worth up to $698m + royalties Agreement with US-based Elevar Therapeutics, subsidiary of South Korea’s HLB $20 M Upfront payment Double digit royalties on global % Apealea® sales Milestones based on regulatory and $678M sales achievements Oasmia retains sole control ove
Slide 12: Oasmia's business model
Oasmia’s business model Partner Improve Develop Commercialise In-licensing Specialist and Proprietary manufacturing, Global out- collaborations technologies clinical, licensing regulatory Model successfully applied to Apealea®, out-licensed globally to Elevar Therapeutics 12
Slide 13: In-licensing opportunities mainly in oncology
In-licensing opportunities mainly in oncology Registration / Pre-clinical Phase I Phase II Phase III approval Marketed • Oasmia is also open to collaborations to support partners’ R&D and overcome solubility challenges Arrange a meeting with us via the BioEurope partnering system to find out more…..
Slide 14: Out-licensing opportunities in animal health portfolio
Out-licensing opportunities in animal health portfolio Paccal Vet Doxophos Vet • A new XR-17™-based formulation of paclitaxel in • A patented formulation of doxorubicin in development for the treatment of mastocytoma in combination with XR-17™ dogs • In development for the treatment of lymphoma, one
Slide 15: Building a sustainable, profitable specialty pharma company
Building a sustainable, profitable specialty pharma company APEALEA® APPROVED A GLOBAL A GROWING WELL POSITIONED FOR IN EUROPE PARTNERSHIP ONCOLOGY PIPELINE PARTNERING / M&A Lead product Elevar Apealea® deal Underpinned by Proven development, launched for worth up to $678 strong IP protection regula
Slide 16: Contact us for more information
Contact us for more information Find out more about our partnering opportunities by emailing our partnering team at: partners@oasmia.com 16